InVivo Therapeutics Holdings Corp. (NVIV) announced the appointment of Christopher McNulty as Chief Financial Officer (CFO), effective March 29, 2017. He will be taking over for the interim CFO, Melanie Morel-Ferris, CPA, who will remain as the company’s Senior Director, Finance and Controller. Prior to being appointed Chief Financial Officer, Mr. McNulty served at InVivo as Senior Vice President, Business Development and Investor Relations, where he was responsible for evaluating all partnerships and licensing opportunities. In addition to his responsibilities in business development, Mr. McNulty played a key role in the company’s financings, including a follow-on offering and registered direct financing totaling an aggregate value of more than $40 million. Prior to joining InVivo, Mr. McNulty served as Senior Director, Business Development of Repligen Corporation.